NeurologyLive Staff

 staff prepares this preview of what to expect from our coverage. This week on 

, there are a number of hot topics that we will be posting throughout the week.

On Monday, November 30, 2020, a new segment from the “Expert Perspectives: Advances in the Management of Acute Migraine,” Insights series will go live. It features Amaal J. Starling, MD, a key opinion leader in migraine, who considers the importance of the pain freedom end point, and discusses the American Headache Society and American Academy of Neurology guidelines for the treatment of acute setting.

Tune in on Tuesday, December 1, 2020, to watch 

conversation with Jude Savarraj, PhD, research scientist, Department of Neurosurgery, The University of Texas Medical School at Houston. He discussed his team’s new study investigating the performance of a machine learning model to predict outcomes in subarachnoid hemorrhage care. Savarraj discusses how his model outperformed standard models, but how physician insight is still critical to its success.

For more conversations with the experts, 

The latest in our NeuroVoices series, dedicated to conversations with leaders in the neurology community, will go live on Wednesday, December 2, 2020. This edition will feature epilepsy specialist Martina Bebin, MD, MPA, in honor of Infantile Spasms Awareness Week. Bebin, who currently serves as a professor of neurology and pediatrics at the University of Alabama at Birmingham Epilepsy Center, discussed the importance of raising awareness towards infantile spasms, challenges associated with the disease, and treatment options available and on the horizon.

A conversation with Dileep Yavagal, MD, professor of clinical neurology, University of Miami, past-president, Society of Vascular and Interventional Neurology, and chair, Mechanical Thrombectomy 2020+ (MT2020+), will air on 

 channel this Thursday, November 19, 2020. Yavagal discussed the MT2020+ initiative and its goals, as well as the gaps and progress in getting greater access to the procedure for patients with stroke.

To check out what's on the Medical World News channel now, 

 "Mind Moments" podcast will air on Friday, December 4, 2020. The episode will feature an exclusive interview with Merle Diamond, MD, president and managing director, Diamond Headache Clinic, in Chicago, Illinois. She discussed her real-world experience with the newest additions to the acute migraine treatment paradigm and their impact on clinical practice, as well as the most promising therapies in the pipeline and what's to come heading into next year.

To subscribe on your favorite podcast player, 

Articles

Here's what is coming soon to NeurologyLive.

This Week on NeurologyLive — November 30, 2020

This week Neurology News Network covered the new drug application submission for INP104, an acute migraine agent, more results on the efficacy of sodium oxybate in patients with type 1 narcolepsy, and a study that evaluated the effects of health-deficit accumulation on cognitive impairment. 

Welcome to this special edition of Neurology News Network. I’m Marco Meglio. Please excuse our appearance this week as a majority of the US workforce, including the 

team, moves to working remote as we come together to help reduce the spread of the novel coronavirus.

According to a recent announcement, Impel NeuroPharma has submitted a 

 (NDA) to the FDA for its investigational migraine treatment, INP104. The therapy is delivered by Impel’s precision olfactory delivery (POD) platform. The NDA is supported by the phase 3, open-label STOP-301 study that included 360 patients with acute migraine, with or without aura, at 36 sites. The study included more than 5650 migraine attacks treated over the course of either 24 or 52 weeks. Over the entire 52 weeks, there were no reported drug-related serious AEs. In the Full Safety Set, 66.3% of patients achieved pain relief and 38% of patients achieved pain freedom at 2 hours following their first dose of INP104.The Primary Safety Set, which included 185 patients, showed that 33.1% of patients who took an average of 2 or more doses of INP104 per the 28-day period during the 24-week treatment phase achieved pain freedom at 2 hours. Initial onset of pain relief began as early as 15 minutes for 16.3% of patients and continued to improve over time.

Sodium oxybate, a first-line treatment of type 1 narcolepsy (NT1), has the ability to 

 sleep behavior disorder (RBD) and REM sleep without atonia (RSWA) in patients with NT1, according to a newly published study.The study evaluated 19 children and adolescents with NT1 who underwent 3 months of stable treatment with SO. RSWA, automatically computed by means of the validated REM sleep atonia index (RAI) was significantly improved in patients who received the drug compared to baseline. Study author Giuseppe Plazzi, MD, director, Sleep Laboratory, Department of Neurological Sciences, University of Bologna, and colleagues noted that the treatment “remarkably” reduced complex movements during REM sleep. They wrote that the improvements on RBD and RSWA point to a direct role of the drug in modulating motor control.

, specifically among older Americans, affects the likelihood of progressive cognitive impairment, as well as the likelihood of cognitive improvement independent of the 

 ε4 allele. Investigators calculated a frailty index score using the deficit-accumulation approach in participants aged 50 years and older from the National Alzheimer’s Coordinating Center. Among those not cognitively impaired, each 0.1 increment increase in score were associated with a higher risk of developing mild cognitive impairment and a higher risk of developing dementia. In total, there were 14,490 participants in the study with a mean age of 72.2 years. In the MCI subsample (n = 4717) at baseline, there was a higher degree of frailty that was associated with a lower probability of being reclassified as NCI from MCI, a higher risk of returning to MCI in those who were reclassified as NCI, and a higher risk of progressing to dementia.

For more direct access to expert insight, head to NeurologyLive.com. This has been Neurology News Network. Thanks for watching.

Videos

Neurology News Network for the week ending November 28, 2020. 

NDA For INP104 Submitted, Sodium Oxybate Improves Nocturnal RBD, Health-Deficit Accumulation Leads to Cognitive Impairment

's Friday 5! Every week, the staff compiles 5 highlights of 

's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

 The Future of Multiple Sclerosis Imaging

Pascal Sati, PhD, explores how advanced imaging technology is on a collision course with artificial intelligence in what is shaping up to be a revolutionary period for the diagnosis and management of MS.

 NeuroVoices: Michael Okun, MD, on Reforming the Device Approval Process

Michael Okun, MD, executive director of the Norman Fixel Institute for Neurological Diseases sat down to discuss his viewpoint paper on changing the approval system for neurotechnological devices in rare diseases.

 Peer Exchange: Misdiagnosis of Multiple Sclerosis

In this episode, the panel of Fred Lublin, MD; Patricia K. Coyle, MD; Scott Newsome, DO, MSCS, FAAN; and Mark Freedman, MD, discuss their clinical work-up criteria, including the use of cerebral spinal fluid, to make a more accurate multiple sclerosis diagnosis.

 James Grotta, MD: The Future of Stroke Care Going into 2021

The vascular neurologist at Memorial Hermann Medical Group explained how clinical stroke care will change in 2021 amid the COVID-19 pandemic, including the importance of MCUs and how telemedicine and televisits will help patients adhere to a more rigid treatment regimen.

Madison Hansen, of the Department of Neurology and Neurotherapeutics, and the Neuroinnovation and Multiple Sclerosis and Neuroimmunology Imaging Programs,  UT Southwestern Medical Center, discussed effectively navigating the nuances of this unique patient population will ultimately help drive innovative solutions for this generation and those to come.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 27, 2020.

NeurologyLive Friday 5 — November 27, 2020

The third segment of the "Updates in the Management of Relapsing Multiple Sclerosis" Peer Exchange premieres Monday, November 23, 2020, and focuses on the misdiagnosis of multiple sclerosis. The panelists discussed their clinical workup criteria, including the use of cerebrospinal fluid, to make a more accurate multiple sclerosis diagnosis. They also touch on the importance of misdiagnosis and how it can impact patients if they are recommended the wrong treatments.

Also going live on Tuesday is a piece from our October 2020 special issue titled, "The Future of Multiple Sclerosis Imaging," authored by Pascal Sati, PhD, director, Neuroimaging Program, Department of Neurology, Cedars-Sinai Medical Center. Sati discussed how advanced imaging technology is on a collision course with artificial intelligence, and how that intersection is shaping up to be a revolutionary period for the diagnosis and management of MS.

On Wednesday, November 25, 2020, the latest edition of our NeuroVoices series goes live, this time featuring Michael S. Okun, MD, executive director, Norman Fixel Institute for Neurological Diseases, University of Florida. Okun sat down to discuss his recently published editorial on reforming the process for deep brain stimulation and neurologic device approval in rare diseases. Specifically, he covers the barriers placed by insurance companies, recommendations for more disease-based registries, and his call to action for what needs to change.

A conversation with Steven Arnold, MD, professor of neurology, Harvard Medical School, and managing director, Interdisciplinary Brain Center, Massachusetts General Hospital, will air on 

 channel this Thursday, November 26, 2020. Arnold discussed the latest on the ongoing phase 2 PEGASUS trial of AMX0035 in Alzheimer disease.

NeurologyLive Staff

Articles

This Week on NeurologyLive — November 30, 2020

NDA For INP104 Submitted, Sodium Oxybate Improves Nocturnal RBD, Health-Deficit Accumulation Leads to Cognitive Impairment

NeurologyLive Friday 5 — November 27, 2020

This Week on NeurologyLive — November 23, 2020